Dawn's pale light filtered through the floor‑to‑ceiling glass of NovaGene's central lab, illuminating rows of stem‑cell incubators and high‑throughput sequencers. Nova Jin stood at the heart of it, tablet in hand, flanked by Selene Park and the chair of the new Ethics Committee, Dr. Haruto Nakamura. Security personnel in dark suits monitored live drone feeds on a wall of screens.
“It's a beautiful morning to change the world," Nova murmured, checking the readouts. “Our gene‑editing prototype is ready for the next phase."
Dr. Nakamura nodded. “All protocols are cleared, and patient consent forms are archived on immutable ledgers. We're about to launch the first transparent human trial."
A siren shrieked—deep, mechanical, and unmissable. The security chief barked into his earpiece: “Multi
